SPECIFIC FEATURES OF LIPID EXCHANGE IN PULMONARY TUBERCULOSIS PATIENTS WITH CONCURRENT DIABETES OF TYPE 1 AND 2
https://doi.org/10.21292/2075-1230-2016-94-9-65-72
Abstract
73 pulmonary tuberculosis patients with concurrent diabetes were examined, ofthem 28 patients suffered from diabetes oftype 1 (D1) and 45 patients had diabetes of type 2 (D2). The following was tested in the blood serum: triglycerides (TG), general cholesterol (GC), high density lipoproteins cholesterol (HDLC) and low density lipoproteins cholesterol (LDLC). Very low density lipoproteins cholesterol (VLDLC) was estimated as perthe following formula: VLDLC = C – (C-HDLC + C-LDLC). Atherogenicity coefficient and atherogenic plasma index were estimated. It was found that pulmonary tuberculosis patients with concurrent diabetes manifested atherogenic changes in respect of lipid exchange: minor changes in D1 and greater changes in D2. Intensity ofsystem inflammatory response syndrome (SIRS) and nutritive status ofthe host provided significant impact on the state of lipid exchange in those suffering from the concurrent conditions. SIRS was related to reduction of cholesterol transporting function of HDLC which reduced anti-atherogenic blood potential. Besides development of SIRS results in the reduction of nutritive status, and the increase of catabolic process in lipid metabolism becomes the part of the above. Intensification of lipolysis is accompanied by the increase of VLDL which together with reduction of HDL defines atherogenic changes in lipid exchange in those suffering from the concurrent conditions. As nutritional insufficiency increases, synthesis of cholesterol becomes lower than the consumption and the level of its circulation (and within atherogenic lipids) goes down which provided anti-atherogenic effect, more intensive in D1. SIRS provides dominating influence on the state of lipid exchange in those suffering from the concurrent conditions.
About the Authors
G. O. Kaminskaya
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Doctor of Medical sciences, Professor, Chief Researcher of Pathologic anatomy and Biochemistry Department,
2, Yauzskaya alleya, Moscow, 107564
R. Yu. Abdullaev
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Doctor of Medical sciences, Professor, senior Researcher, Head of Biochemical laboratory,
2, Yauzskaya alleya, Moscow, 107564
O. G. Komissarova
Central Tuberculosis Research Institute
Russian Federation
Russian Federation
Doctor of Medical sciences, Deputy Director for Research and Therapy,
2, Yauzskaya alleya, Moscow, 107564
References
1. Gridina G.D. Nekotorye mekhanizmy narusheniy lipidnogo obmena pri tuberkuleze legkikh. Diss. kand. biol. nauk. [Certain mechanisms of lipid metabolism disorders in case of pulmonary tuberculosis. Cand. Diss.]. Moscow, 1970.
2. Gurevich G.L. Znachenie issledovaniya pokazateley obmena lipidov u bolnykh s vpervye vyyavlennym tuberkulezom legkikh. Diss. kand. med. nauk. [The value of studying the lipid metabolism rates new pulmonary tuberculosis patients. Cand. Diss.]. Minsk, 1982.
3. Kaminskaya G.O. Sostoyanie lipidnogo obmena u bolnykh tuberkulezom v usloviyakh sovremennogo kompleksnogo lecheniya. Diss. kand. med. nauk. [State of lipid metabolism in tuberculosis patents under the condition of modern integrated treatment. Cand. Diss.]. Moscow, 1965.
4. Kaminskaya G.O., Аbdullaev R.Yu., Komisarova O.G. Rates of transthyretin (pre-albumin) in blood serum of pulmonary tuberculosis patients. Tub. i Bolezni Legkikh, 2012, no. 3, pp. 52-56. (In Russ.)
5. Kaminskaya G.O., Аbdullaev R.Yu., Komisarova O.G. State of protein exchange as a factor of non-specific host response in pulmonary tuberculosis patients. Tub. i Bolezni Legkikh, 2012, no. 12, pp. 30-35. (In Russ.)
6. Kamyshnikov V.S. Osobennosti kholesterinopatii i aterogeneza pri legochnoy patologii. Diss. dokt. med. nauk. [Specific cholesterol disorders and atherogenesis in pulmonary pathology. Doct. Diss.]. Moscow, 1990.
7. Karachunskiy M.А., Beglaryan N.R., Yakovleva O.B. Specific symptoms and course of tuberculosis in those with borderline disorders of carbohydrate metabolism. Probl. Tub., 1993, no. 5, pp. 16-17. (In Russ.)
8. Keleberda K.Ya. Tuberkulez legkikh u bolnykh sakharnym diabetom (kliniko-eksperimentalnoe issledovanie). Diss. dokt. med. nauk. [Pulmonary tuberculosis in diabetes patients (clinical experimental study). Doct. Diss.]. Moscow, 1966.
9. Klinicheskaya interpretatsiya laboratornykh issledovaniy. [Clinical interpretation of laboratory tests]. Ed. by A.B. Belevitin and S.G. Scherbak, St. Petersburg, 2006, pp. 120-133.
10. Kovaleva S.I. Sakharny diabet i tuberkulez (dispansernoe issledovanie). Diss. dokt. med. nauk. [Diabetes and tuberculosis (dispensary follow-up). Doct. Diss.]. Moscow, 1979.
11. Korovkin V.S. Tuberkulez legkikh u bolnykh sakharnym diabetom i osobennosti patofiziologicheskikh rasstroystv funktsiy endokrinnykh i parenkhimatozmykh organov. Diss. dokt. med. nauk. [Pulmonary tuberculosis in diabetes patients and specifics of pathophysiological disorders of endocrine and parenchymal organs. Doct. Diss.]. Moscow, 1979.
12. Mazovetskiy А.G., Velikov V.K. Sakharny Diabet. [Diabetes]. Moscow, 1987.
13. Martynov S.A. Dislipidemiya kak faktor riska sosudistykh oslozhneniy sakharnogo diabeta. Sakharny diabet: ostrye i khronicheskie oslozhneniya. [Dislipidemy as a risk factor of vascular complications of diabetes. Diabetes: acute and chronic complications]. Ed. by I.I. Dedov and M.V. Shestakova. Moscow, 2011. pp. 107-115.
14. Mkrtumyan А.F. Treatment of diabetes and its complications. Ross. Med. Journal, 2002, 65, no. 17, pp. 773-777. (In Russ.)
15. Safaryan M.D. Vzaimosvyaz techeniya tuberkuleza legkikh s sostoyaniem lipidnogo i belkovogo obmena i klinicheskaya effektivnost’ ikh korrektsii v protsesse kompleksnoy khimioterapii. Diss. dokt. med. nauk. [Correlation between the course of pulmonary tuberculosis and lipid and protein metabolism and clinical efficiency of their management within integrated chemotherapy. Doct. Diss.]. Moscow, 1992.
16. Smurova T.F. Tuberkulez legkikh i sakharny diabet. Diss. dokt. med. nauk. [Pulmonary tuberculosis and diabetes. Doct. Diss.] Moscow, 1974.
17. Smurova T.F., Kovaleva S.I. Tuberkulez i sakharny diabet. [Tuberculosis and diabetes]. Moscow, 2007.
18. Tvorogov M.G. Lipidy i lipoproteidy: spravochnoe posobie. [Lipids and lipoproteins: handbook]. Moscow, 2010.
19. Titov V.N. Clinical biochemistry of lypolipidemic therapy and statins action mechanisms. Fatty acids, statins and diabetes. Clin. Lab. Diagn., 2014, no. 2, pp. 4-15. (In Russ.)
20. Titov V.N. Establishment in phylogenesis of fat cells, biological function of trophology, biological reactions of exo- and endotrophia, functional difference between visceral fat cells and subcutaneous adipocytes. Clin. Lab. Diagn., 2015, no. 2, pp. 4-12. (In Russ.)
21. Titov V.N., Rozhkova T.А., Аmelyushkina V.А. Clinical biochemistry of hyperlipilemia and hyperglycemia, insulin and fatty acids metabolism. Hypoglycemic action of hypolipidemic agents. Clin. Lab. Diagn., 2014, no. 3, pp. 4-13. (InRuss.)
22. Chernykh N.A. Effektivnost intensivnoy khimioterapii tuberkuleza legkikh u bolnykh sakharnym diabetom. Diss. kand. med. nauk. [Efficiency of intensive chemotherapy of pulmonary tuberculosis with concurrent diabetes. Cand. Diss.]. Moscow, 2004.
23. Chumakova O.S., Zateyschikov D.А., Sidorenko B.А. Apolipoprotein B: structure, functions, gene polymorphism and correlation with atherosclerosis. Kardiologia, 2005, vol. 45, no. 6, pp. 43-55. (In Russ.)
24. Shestakova M.V., Sukhareva O.Yu. Diabetes of type 2: is it easy to prevent it and can it be cured? Consilium Medicum. 2012, vol. 14, no. 12, pp. 5-9. (In Russ.)
25. Ahmad N.H., Sakri F., Mokhin A. et al. Low serum high density lipoprotein cholesterol concentration is an independent predictor for enhanced inflammation and endothelium activation. PLOS ONE, (doi: 10.1371 / journal pone. 0116867 january 23.2015).
26. Martens G.W., Arikan M.C., Lee J. et al. Hypercholesterolemia impairs immunity to tuberculosis. Infection and Immunity, 2008, vol. 76, no. 8, pp. 3464-3472.
27. Qullet H., Johnston J.B., Oritz de Montellano P.R. Cholesterol catabolism as a therapeutic target in Mycobacterium tuberculosis. Trends Microbiol., 2011, vol. 18, no. 11, pp. 530-539.
28. Thomas S.T., Vander Ven B.C., Sherman D.R. et al. Pathway profiling in Mycobacterium tuberculosis. Elucidation of cholesterol-derived catabolite and enzymes that catalyse its metabolism. J. Biol. Chem., 2011, vol. 286, no. 51, pp. 43668-43678.
29. van der Oever J.A.M., Raterman H.G., Nurmohamed M.T., Simsek S. Endothelium dysfunction, inflammation and apoptosis in diabetes mellitus. Mediators of Inflammation.– 2010; doi:10.1155/ 2010/ 792393.
30. Vander Ven B.C., Fathey R.J., Lee W. et al. Novel inhibitors of cholesterol degradation in Mycobacteriumtuberculosis reveal how the bacterium, s metabolism is contrained by the intracellular environment. PLoS Pathol 11(2): e 1004679; doi: 10.1371 / journal ppat.1004679.
Review
For citations:
Kaminskaya G.O., Abdullaev R.Yu., Komissarova O.G. SPECIFIC FEATURES OF LIPID EXCHANGE IN PULMONARY TUBERCULOSIS PATIENTS WITH CONCURRENT DIABETES OF TYPE 1 AND 2. Tuberculosis and Lung Diseases. 2016;94(9):65-72. (In Russ.) https://doi.org/10.21292/2075-1230-2016-94-9-65-72
Views:
983
Email this article 